11 Stocks with Consistent Growth to Buy Now

8. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

5-Year Average Growth Rate: 75.17%

No. of Hedge Funds: 35

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a Florida-based company, is developing therapies for rare neurological diseases. The company takes pride in its lead product, Firdapse®, which treats Lambert-Eaton myasthenic syndrome (LEMS) with limited treatment options. Competing with other rare disease firms, it uses lifecycle management strategies, orphan drug exclusivity, and selective in-licensing of pipeline assets to gain a competitive advantage. In particular, focusing on neuromuscular disorders enables the company to deliver sustained growth within underserved patient populations. It is one of the best stocks with consistent growth.

Strategic drug development alongside niche targeting has helped achieve a 75.17% growth average rate in the past 5-year period. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has reported a record total revenue of $141.8 million in the fourth quarter of 2024, a 28.3% increase compared to the same period in the prior year. Firdapse and Agamree heavily contributed to this revenue growth. With continued growth in these two products, the company anticipates a total revenue between $545 million and $565 million for 2025. Additionally, having completed 2024 with no debt and a massive cash position of $517.6 million, the company has expanded its capacity to invest in strategic growth opportunities.

Currently backed by 35 hedge funds, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) represents a mid-cap biotech with long-term consistent growth that may interest investors focusing on high-growth pharmaceutical stocks.